Lexaria Bioscience Corp (LEXX)

[damAcon1]

As at August 31, 2020, we had a working capital surplus of $1,700,044 and cash on hand of $1,293,749. We estimate our minimum necessary expenses for the year to be roughly $2.5 million in which case we would require
approximately $1.2 million in additional financed cash to meet our minimum level of expenditures. These necessary expenses include professional fees, wages and general and administrative expenses necessary to satisfy our public reporting requirements.

During the next twelve­ month period (beginning September 1, 2020), we intend to:
· pursue a listing on a U.S. senior stock exchange or market;
· pursue technology out ­licensing opportunities for our patented DehydraTECH technology. This will be focused first primarily on the CBD­-from hemp and nicotine sectors, and will evolve as time allows for completed R&D in other sectors, to the NSAID, and will eventually include the anti viral drug sectors if and as our R&D supports such initiatives;
· identify and secure sources of equity and/or debt financing for intellectual property pursuit and maintenance, R&D, and consumer product
formulation and marketing and general corporate operations;